Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026

Veru advances obesity and pancreatic cancer drug trials but faces long timelines and high risks.

What the company is saying

Veru Inc. is highlighting its clinical development progress in obesity and oncology, focusing on two late-stage drug candidates: enobosarm and sabizabulin. The company is promoting a podium presentation at ObesityWeek 2026 by Chief Scientific Officer Dr. Gary Barnette, featuring results from a post hoc analysis in patients aged 65 and older from the positive Phase 2b QUALITY study. The announcement emphasizes over-enrollment in the Phase 2b PLATEAU trial (239 patients vs. 200 target) and sets expectations for interim data in Q1 2027 and topline results in Q4 2027. Veru frames enobosarm as a next-generation therapy for quality weight loss and preservation of lean mass in combination with GLP-1 RA drugs, and positions sabizabulin as a potential treatment for KRAS-driven metastatic pancreatic cancer resistant to daraxonrasib. The company plans a Phase 2b study for sabizabulin and will seek FDA regulatory clarity in Q4 2026. The tone is optimistic, with repeated references to positive study outcomes and unmet medical need, but most efficacy claims for sabizabulin remain forward-looking.

What the data suggests

The company reports exceeding enrollment targets in its Phase 2b PLATEAU obesity trial, enrolling 239 patients versus the planned 200, and completed a 168-patient Phase 2b QUALITY study in older adults. The PLATEAU trial’s primary endpoint is percent change in total body weight at 68 weeks, with secondary endpoints including fat mass, lean mass, physical function, bone mineral density, and metabolic markers. Interim data from PLATEAU are expected in Q1 2027, with topline data in Q4 2027. The completed QUALITY study showed that enobosarm plus semaglutide preserved lean mass and physical function, with greater fat loss during active weight loss, and that enobosarm monotherapy prevented weight regain after GLP-1 RA discontinuation. For pancreatic cancer, the release cites 67,530 new cases and 52,740 deaths expected in the United States in 2026, with a five-year survival rate of ~12.5% and over 90% of tumors harboring KRAS mutations. Up to 85% of patients present with advanced or metastatic disease, and only 15–20% are eligible for surgery. Sabizabulin’s efficacy is described as preclinical or early clinical, with no pivotal trial data disclosed. No financial metrics, revenue, or funding details are provided.

Analysis

The announcement is upbeat, highlighting both realised milestones (e.g., completion of Phase 2b QUALITY study, over-enrollment in the PLATEAU trial) and a number of forward-looking claims regarding future clinical development and potential drug impact. While the company provides concrete operational data (enrollment numbers, study endpoints, timelines), the most significant value drivers—such as the efficacy of sabizabulin in pancreatic cancer and the incremental benefit of enobosarm—remain unproven and are described in aspirational terms. The timeline for meaningful clinical readouts is long (interim data in Q1 2027, topline in Q4 2027), and the company is planning a capital-intensive Phase 2b study for sabizabulin without disclosing funding or near-term earnings impact. The language around 'next generation' and 'potential to become the next treatment' inflates expectations relative to the current evidence, which is limited to preclinical or early clinical signals. No financial or profitability metrics are disclosed, so the true_signal cannot exceed weak_positive.

Risk flags

• ●The primary value drivers—enobosarm’s incremental benefit and sabizabulin’s efficacy in resistant pancreatic cancer—are not yet supported by pivotal clinical data, making future success highly uncertain.
• ●The timeline to meaningful data is long, with topline PLATEAU results not expected until Q4 2027, increasing the risk of delays, trial attrition, or changing competitive dynamics before value can be realized.
• ●The company is planning a capital-intensive Phase 2b study for sabizabulin but has not disclosed funding sources or financial runway, raising concerns about potential dilution or financing risk.
• ●Sabizabulin’s claims are based on preclinical and early clinical data, and the leap to clinical efficacy in a highly lethal, genomically homogeneous cancer with a 4-month median survival is unproven.
• ●No financial data, cash position, or burn rate is disclosed, limiting visibility into the company’s ability to sustain operations through these long timelines.

Bottom line

Veru is making operational progress in its obesity and oncology pipeline, with over-enrollment in the PLATEAU trial and a positive readout from the QUALITY study supporting enobosarm’s potential to improve weight loss quality in older adults. The company is also positioning sabizabulin as a future therapy for KRAS-driven metastatic pancreatic cancer, but this is still at the pre-IND planning stage, with efficacy claims resting on preclinical and early clinical evidence. All major clinical catalysts are at least several months to over a year away, and the absence of financial disclosures or funding details adds uncertainty about the company’s ability to execute its plans. Investors should recognize that while the clinical rationale is compelling, the path to value is long and high risk, with no near-term revenue or pivotal data expected. The most important takeaway is that Veru’s story remains a high-risk, long-duration bet on unproven late-stage assets, with execution and financing as key hurdles.

Announcement summary

(NASDAQ: VERU) Veru Inc. announced that its Chief Scientific Officer, Dr. Gary Barnette, will deliver a podium presentation at ObesityWeek 2026 in Washington DC, presenting results from a post hoc analysis of physical function in patients aged 65 years and older with obesity receiving a GLP-1 RA from the positive Phase 2b QUALITY study. The presentation, titled 'Enobosarm in Patients with Obesity on Semaglutide: Quality Weight Loss & Better Physical Function,' is scheduled for November 16, 2026, from 5:15 PM to 5:30 PM Eastern Standard Time. Veru's drug development program includes two late-stage novel small molecules: enobosarm, an oral selective androgen receptor modulator (SARM), and sabizabulin, an oral microtubule targeting agent. Enobosarm is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, aiming to improve body composition and physical function and to achieve clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone. Sabizabulin has demonstrated potential in preclinical and clinical studies to become a treatment for KRAS-driven metastatic pancreatic cancer resistant to daraxonrasib. The company plans to pursue a Phase 2b clinical study to evaluate sabizabulin in metastatic pancreatic cancer after daraxonrasib failure and will seek regulatory clarity from the FDA through a preIND meeting in Q4 2026. The Phase 2b PLATEAU clinical trial, a double-blind, placebo-controlled study, evaluates enobosarm 3mg in older patients (age ≥ 65 years) with obesity (BMI ≥ 35) initiating semaglutide treatment. The company exceeded its targeted full enrollment of 200 patients by enrolling 239 patients. The primary efficacy endpoint is percent change from baseline in total body weight at 68 weeks, with key secondary endpoints including total fat mass, total lean mass, physical function, mobility disability assessment, bone mineral density, and patient-reported outcomes for physical function, HbA1c, and insulin resistance. Interim analysis results assessing lean body mass and fat mass after 32 weeks are expected in Q1 2027, and final topline clinical data is expected in Q4 2027. The Principal Investigator for the PLATEAU trial is Steven Heymsfield, MD, who was also the Principal Investigator for the Phase 2 QUALITY clinical study. The completed Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding trial evaluating enobosarm 3 mg, enobosarm 6 mg, or placebo in 168 older patients (≥60 years) receiving semaglutide for weight reduction. After 16 weeks, participants entered a maintenance extension where all discontinued semaglutide but continued on placebo or enobosarm for 12 weeks. The study demonstrated that enobosarm plus semaglutide preserved lean mass and physical function and led to greater fat loss during the active weight loss period, and enobosarm monotherapy prevented weight regain and continued fat mass loss after GLP-1 RA discontinuation. Pancreatic cancer is projected to have 67,530 new cases and 52,740 deaths in the United States in 2026, with only ~12.5 % of patients expected to survive 5 years following diagnosis. Only 15—20% of patients are eligible for surgery, and up to 85 % present with locally advanced or metastatic disease. More than 90% of pancreatic cancer tumors have a KRAS oncogene mutation. βIII-tubulin aberrant expression is commonly observed in up to 90% of pancreatic adenocarcinoma cancers.

Disagree with this article?